Cargando…

A Practical Guide to Immunoassay Method Validation

Biochemical markers have a central position in the diagnosis and management of patients in clinical medicine, and also in clinical research and drug development, also for brain disorders, such as Alzheimer’s disease. The enzyme-linked immunosorbent assay (ELISA) is frequently used for measurement of...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreasson, Ulf, Perret-Liaudet, Armand, van Waalwijk van Doorn, Linda J. C., Blennow, Kaj, Chiasserini, Davide, Engelborghs, Sebastiaan, Fladby, Tormod, Genc, Sermin, Kruse, Niels, Kuiperij, H. Bea, Kulic, Luka, Lewczuk, Piotr, Mollenhauer, Brit, Mroczko, Barbara, Parnetti, Lucilla, Vanmechelen, Eugeen, Verbeek, Marcel M., Winblad, Bengt, Zetterberg, Henrik, Koel-Simmelink, Marleen, Teunissen, Charlotte E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541289/
https://www.ncbi.nlm.nih.gov/pubmed/26347708
http://dx.doi.org/10.3389/fneur.2015.00179
_version_ 1782386368778862592
author Andreasson, Ulf
Perret-Liaudet, Armand
van Waalwijk van Doorn, Linda J. C.
Blennow, Kaj
Chiasserini, Davide
Engelborghs, Sebastiaan
Fladby, Tormod
Genc, Sermin
Kruse, Niels
Kuiperij, H. Bea
Kulic, Luka
Lewczuk, Piotr
Mollenhauer, Brit
Mroczko, Barbara
Parnetti, Lucilla
Vanmechelen, Eugeen
Verbeek, Marcel M.
Winblad, Bengt
Zetterberg, Henrik
Koel-Simmelink, Marleen
Teunissen, Charlotte E.
author_facet Andreasson, Ulf
Perret-Liaudet, Armand
van Waalwijk van Doorn, Linda J. C.
Blennow, Kaj
Chiasserini, Davide
Engelborghs, Sebastiaan
Fladby, Tormod
Genc, Sermin
Kruse, Niels
Kuiperij, H. Bea
Kulic, Luka
Lewczuk, Piotr
Mollenhauer, Brit
Mroczko, Barbara
Parnetti, Lucilla
Vanmechelen, Eugeen
Verbeek, Marcel M.
Winblad, Bengt
Zetterberg, Henrik
Koel-Simmelink, Marleen
Teunissen, Charlotte E.
author_sort Andreasson, Ulf
collection PubMed
description Biochemical markers have a central position in the diagnosis and management of patients in clinical medicine, and also in clinical research and drug development, also for brain disorders, such as Alzheimer’s disease. The enzyme-linked immunosorbent assay (ELISA) is frequently used for measurement of low-abundance biomarkers. However, the quality of ELISA methods varies, which may introduce both systematic and random errors. This urges the need for more rigorous control of assay performance, regardless of its use in a research setting, in clinical routine, or drug development. The aim of a method validation is to present objective evidence that a method fulfills the requirements for its intended use. Although much has been published on which parameters to investigate in a method validation, less is available on a detailed level on how to perform the corresponding experiments. To remedy this, standard operating procedures (SOPs) with step-by-step instructions for a number of different validation parameters is included in the present work together with a validation report template, which allow for a well-ordered presentation of the results. Even though the SOPs were developed with the intended use for immunochemical methods and to be used for multicenter evaluations, most of them are generic and can be used for other technologies as well.
format Online
Article
Text
id pubmed-4541289
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-45412892015-09-07 A Practical Guide to Immunoassay Method Validation Andreasson, Ulf Perret-Liaudet, Armand van Waalwijk van Doorn, Linda J. C. Blennow, Kaj Chiasserini, Davide Engelborghs, Sebastiaan Fladby, Tormod Genc, Sermin Kruse, Niels Kuiperij, H. Bea Kulic, Luka Lewczuk, Piotr Mollenhauer, Brit Mroczko, Barbara Parnetti, Lucilla Vanmechelen, Eugeen Verbeek, Marcel M. Winblad, Bengt Zetterberg, Henrik Koel-Simmelink, Marleen Teunissen, Charlotte E. Front Neurol Neuroscience Biochemical markers have a central position in the diagnosis and management of patients in clinical medicine, and also in clinical research and drug development, also for brain disorders, such as Alzheimer’s disease. The enzyme-linked immunosorbent assay (ELISA) is frequently used for measurement of low-abundance biomarkers. However, the quality of ELISA methods varies, which may introduce both systematic and random errors. This urges the need for more rigorous control of assay performance, regardless of its use in a research setting, in clinical routine, or drug development. The aim of a method validation is to present objective evidence that a method fulfills the requirements for its intended use. Although much has been published on which parameters to investigate in a method validation, less is available on a detailed level on how to perform the corresponding experiments. To remedy this, standard operating procedures (SOPs) with step-by-step instructions for a number of different validation parameters is included in the present work together with a validation report template, which allow for a well-ordered presentation of the results. Even though the SOPs were developed with the intended use for immunochemical methods and to be used for multicenter evaluations, most of them are generic and can be used for other technologies as well. Frontiers Media S.A. 2015-08-19 /pmc/articles/PMC4541289/ /pubmed/26347708 http://dx.doi.org/10.3389/fneur.2015.00179 Text en Copyright © 2015 Andreasson, Perret-Liaudet, van Waalwijk van Doorn, Blennow, Chiasserini, Engelborghs, Fladby, Genc, Kruse, Kuiperij, Kulic, Lewczuk, Mollenhauer, Mroczko, Parnetti, Vanmechelen, Verbeek, Winblad, Zetterberg, Koel-Simmelink and Teunissen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Andreasson, Ulf
Perret-Liaudet, Armand
van Waalwijk van Doorn, Linda J. C.
Blennow, Kaj
Chiasserini, Davide
Engelborghs, Sebastiaan
Fladby, Tormod
Genc, Sermin
Kruse, Niels
Kuiperij, H. Bea
Kulic, Luka
Lewczuk, Piotr
Mollenhauer, Brit
Mroczko, Barbara
Parnetti, Lucilla
Vanmechelen, Eugeen
Verbeek, Marcel M.
Winblad, Bengt
Zetterberg, Henrik
Koel-Simmelink, Marleen
Teunissen, Charlotte E.
A Practical Guide to Immunoassay Method Validation
title A Practical Guide to Immunoassay Method Validation
title_full A Practical Guide to Immunoassay Method Validation
title_fullStr A Practical Guide to Immunoassay Method Validation
title_full_unstemmed A Practical Guide to Immunoassay Method Validation
title_short A Practical Guide to Immunoassay Method Validation
title_sort practical guide to immunoassay method validation
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541289/
https://www.ncbi.nlm.nih.gov/pubmed/26347708
http://dx.doi.org/10.3389/fneur.2015.00179
work_keys_str_mv AT andreassonulf apracticalguidetoimmunoassaymethodvalidation
AT perretliaudetarmand apracticalguidetoimmunoassaymethodvalidation
AT vanwaalwijkvandoornlindajc apracticalguidetoimmunoassaymethodvalidation
AT blennowkaj apracticalguidetoimmunoassaymethodvalidation
AT chiasserinidavide apracticalguidetoimmunoassaymethodvalidation
AT engelborghssebastiaan apracticalguidetoimmunoassaymethodvalidation
AT fladbytormod apracticalguidetoimmunoassaymethodvalidation
AT gencsermin apracticalguidetoimmunoassaymethodvalidation
AT kruseniels apracticalguidetoimmunoassaymethodvalidation
AT kuiperijhbea apracticalguidetoimmunoassaymethodvalidation
AT kulicluka apracticalguidetoimmunoassaymethodvalidation
AT lewczukpiotr apracticalguidetoimmunoassaymethodvalidation
AT mollenhauerbrit apracticalguidetoimmunoassaymethodvalidation
AT mroczkobarbara apracticalguidetoimmunoassaymethodvalidation
AT parnettilucilla apracticalguidetoimmunoassaymethodvalidation
AT vanmecheleneugeen apracticalguidetoimmunoassaymethodvalidation
AT verbeekmarcelm apracticalguidetoimmunoassaymethodvalidation
AT winbladbengt apracticalguidetoimmunoassaymethodvalidation
AT zetterberghenrik apracticalguidetoimmunoassaymethodvalidation
AT koelsimmelinkmarleen apracticalguidetoimmunoassaymethodvalidation
AT teunissencharlottee apracticalguidetoimmunoassaymethodvalidation
AT andreassonulf practicalguidetoimmunoassaymethodvalidation
AT perretliaudetarmand practicalguidetoimmunoassaymethodvalidation
AT vanwaalwijkvandoornlindajc practicalguidetoimmunoassaymethodvalidation
AT blennowkaj practicalguidetoimmunoassaymethodvalidation
AT chiasserinidavide practicalguidetoimmunoassaymethodvalidation
AT engelborghssebastiaan practicalguidetoimmunoassaymethodvalidation
AT fladbytormod practicalguidetoimmunoassaymethodvalidation
AT gencsermin practicalguidetoimmunoassaymethodvalidation
AT kruseniels practicalguidetoimmunoassaymethodvalidation
AT kuiperijhbea practicalguidetoimmunoassaymethodvalidation
AT kulicluka practicalguidetoimmunoassaymethodvalidation
AT lewczukpiotr practicalguidetoimmunoassaymethodvalidation
AT mollenhauerbrit practicalguidetoimmunoassaymethodvalidation
AT mroczkobarbara practicalguidetoimmunoassaymethodvalidation
AT parnettilucilla practicalguidetoimmunoassaymethodvalidation
AT vanmecheleneugeen practicalguidetoimmunoassaymethodvalidation
AT verbeekmarcelm practicalguidetoimmunoassaymethodvalidation
AT winbladbengt practicalguidetoimmunoassaymethodvalidation
AT zetterberghenrik practicalguidetoimmunoassaymethodvalidation
AT koelsimmelinkmarleen practicalguidetoimmunoassaymethodvalidation
AT teunissencharlottee practicalguidetoimmunoassaymethodvalidation